NEW YORK (TheStreet) -- RATINGS CHANGES
Abercrombie & Fitch (ANF) was downgraded to market perform from outperform by FBR Capital Markets, which said that brand turnaround may be pushed out and the company is facing increased international competition.
Apollo (APOL) was downgraded to underperform from neutral by Bank of America/Merrill Lynch, which set a $14 price target, saying the company is facing another transition year.
Biocryst (BCRX) was upgraded to buy from neutral by Bank of America/Merrill Lynch, which set a $19 price target, saying Biocryst's new drug is more likely to be approved and would drive future growth.
Fitbit (FIT) was started at outperform by RBC Capital, which set a $45 price target, saying the market is in the early-growth stages and the company can continue to gain market share.
Intersect (XENT) was started at buy by Cantor Fitzgerald, which set a $35 price target, saying the company is unique in offering products to comprehensively treat sinusitis by opening, medicating and maintaining the sinus channels.
Lowe's (LOW) was upgraded to outperform from market perform by BMO Capital, which set an $81 price target. Estimates have also been increased, given higher expected economic activity in the Southeast, BMO said.